Advanced search
Publication Cover
The World Journal of Biological Psychiatry Volume 16, 2015 - Issue 7
Submit an article Journal homepage
436
Views
24
CrossRef citations to date
0
Altmetric
ORIGINAL INVESTIGATION

Two Phase III randomised double-blind studies of fixed-dose TC-5214 (dexmecamylamine) adjunct to ongoing antidepressant therapy in patients with major depressive disorder and an inadequate response to prior antidepressant therapy

Hans-Jürgen MöllerDepartment of Psychiatry, Ludwig-Maximilians University, Munich, GermanyCorrespondence[email protected]
,
Koen DemyttenaereDepartment of Psychiatry, University Hospital Gasthuisberg, Leuven, Belgium
,
Bengt OlaussonFormerly AstraZeneca R&D, Södertälje, Sweden
,
Johan SzamosiFormerly AstraZeneca R&D, Södertälje, Sweden
,
Ellis WilsonFormerly AstraZeneca Pharmaceuticals, Wilmington, DE, USA
,
David HosfordTargacept, Inc., Winston-Salem, NC, USA
,
Geoffrey DunbarFormerly Targacept, Inc., Winston-Salem, NC, USA
,
Raj TummalaAstraZeneca Pharmaceuticals, Wilmington, DE, USA
&
Hans ErikssonFormerly AstraZeneca R&D, Södertälje, Sweden
 show all
Pages 483-501 | Received 22 May 2014, Accepted 13 Oct 2014, Published online: 20 Jan 2015

Citations (24)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Ben Carter, Rebecca Strawbridge, Muhammad Ishrat Husain, Brett D. M. Jones, Roxanna Short, Anthony J. Cleare, Dimosthenis Tsapekos, Fiona Patrick, Lindsey Marwood, Rachael W. Taylor, Tim Mantingh, Valeria de Angel, Viktoriya L. Nikolova, Andre F. Carvalho & Allan H. Young. (2020) Relative effectiveness of augmentation treatments for treatment-resistant depression: a systematic review and network meta-analysis. International Review of Psychiatry 32:5-6, pages 477-490.
Read now
Emmanuelle Weiller, Catherine Weiss, Christopher P Watling, Christopher Edge, Mary Hobart, Hans Eriksson & Maurizio Fava. (2018) Functioning outcomes with adjunctive treatments for major depressive disorder: a systematic review of randomized placebo-controlled studies. Neuropsychiatric Disease and Treatment 14, pages 103-115.
Read now

Articles from other publishers (22)

K.B. Bjugstad & P.R. Sanberg. (2022) The boundlessness of behavioral neuroscience: A look across 30 years. Neuroscience & Biobehavioral Reviews 142, pages 104910.
Crossref
Szilvia Arany, Dorota T. Kopycka-Kedzierawski, Thomas V. Caprio & Gene E. Watson. (2021) Anticholinergic medication: Related dry mouth and effects on the salivary glands. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology 132:6, pages 662-670.
Crossref
Hosna Mohammad Sadeghi, Ida Adeli, Taraneh Mousavi, Marzieh Daniali, Shekoufeh Nikfar & Mohammad Abdollahi. (2021) Drug Repurposing for the Management of Depression: Where Do We Stand Currently?. Life 11:8, pages 774.
Crossref
Sophie R. Vaccarino & Sidney H. Kennedy. 2021. Ketamine for Treatment-Resistant Depression. Ketamine for Treatment-Resistant Depression 33 84 .
Lauren C. Smith & Olivier George. (2020) Advances in smoking cessation pharmacotherapy: Non-nicotinic approaches in animal models. Neuropharmacology 178, pages 108225.
Crossref
Lorenzo Guizzaro, David Dickinson Vaughan Morgan, Andrea Falco & Ciro Gallo. (2020) Hamilton scale and MADRS are interchangeable in meta-analyses but can disagree at trial level. Journal of Clinical Epidemiology 124, pages 106-117.
Crossref
Maurizio Fava, Michael E. Thase, Madhukar H. Trivedi, Elliot Ehrich, William F. Martin, Asli Memisoglu, Narinder Nangia, Arielle D. Stanford, Miao Yu & Sanjeev Pathak. (2018) Opioid system modulation with buprenorphine/samidorphan combination for major depressive disorder: two randomized controlled studies. Molecular Psychiatry 25:7, pages 1580-1591.
Crossref
Alan S. Lewis & Marina R. Picciotto. (2020) Regulation of aggressive behaviors by nicotinic acetylcholine receptors: Animal models, human genetics, and clinical studies. Neuropharmacology 167, pages 107929.
Crossref
M. J. Moerke, L. R. McMahon & J. L. Wilkerson. (2020) More than Smoke and Patches: The Quest for Pharmacotherapies to Treat Tobacco Use Disorder. Pharmacological Reviews 72:2, pages 527-557.
Crossref
Stephanie C. Dulawa & David S. Janowsky. (2018) Cholinergic regulation of mood: from basic and clinical studies to emerging therapeutics. Molecular Psychiatry 24:5, pages 694-709.
Crossref
Patrycja Nowak-Sliwinska, Leonardo Scapozza & Ariel Ruiz i Altaba. (2019) Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1871:2, pages 434-454.
Crossref
Rebecca Strawbridge, Ben Carter, Lindsey Marwood, Borwin Bandelow, Dimosthenis Tsapekos, Viktoriya L. Nikolova, Rachael Taylor, Tim Mantingh, Valeria de Angel, Fiona Patrick, Anthony J. Cleare & Allan H. Young. (2018) Augmentation therapies for treatment-resistant depression: systematic review and meta-analysis. British Journal of Psychiatry 214:1, pages 42-51.
Crossref
C Fabbri, K E Tansey, R H Perlis, J Hauser, N Henigsberg, W Maier, O Mors, A Placentino, M Rietschel, D Souery, G Breen, C Curtis, L Sang-Hyuk, S Newhouse, H Patel, M Guipponi, N Perroud, G Bondolfi, M O'Donovan, G Lewis, J M Biernacka, R M Weinshilboum, A Farmer, K J Aitchison, I Craig, P McGuffin, R Uher & C M Lewis. (2017) New insights into the pharmacogenomics of antidepressant response from the GENDEP and STAR*D studies: rare variant analysis and high-density imputation. The Pharmacogenomics Journal 18:3, pages 413-421.
Crossref
Dina Manetti, Cristina Bellucci, Niccolò Chiaramonte, Silvia Dei, Elisabetta Teodori & Maria Novella Romanelli. (2018) Designing selective modulators for the nicotinic receptor subtypes: challenges and opportunities. Future Medicinal Chemistry 10:4, pages 433-460.
Crossref
Jason A. Gandelman, Paul Newhouse & Warren D. Taylor. (2018) Nicotine and networks: Potential for enhancement of mood and cognition in late-life depression. Neuroscience & Biobehavioral Reviews 84, pages 289-298.
Crossref
Mohamed Elsaed Ebada. (2017) Drug repurposing may generate novel approaches to treating depression. Journal of Pharmacy and Pharmacology 69:11, pages 1428-1436.
Crossref
Nelson Perez-Urrutia, Cristhian Mendoza, Nathalie Alvarez-Ricartes, Patricia Oliveros-Matus, Florencia Echeverria, J. Alex Grizzell, George E. Barreto, Alexandre Iarkov & Valentina Echeverria. (2017) Intranasal cotinine improves memory, and reduces depressive-like behavior, and GFAP + cells loss induced by restraint stress in mice. Experimental Neurology 295, pages 211-221.
Crossref
Eduardo Dunayevich, Robert W Buchanan, Chao-Yin Chen, Jun Yang, Jon Nilsen, Julie M Dietrich, Hong Sun & Stephen Marder. (2017) Efficacy and safety of the glycine transporter type-1 inhibitor AMG 747 for the treatment of negative symptoms associated with schizophrenia. Schizophrenia Research 182, pages 90-97.
Crossref
P.H. HutsonJ.A. ClarkA.J. Cross. (2017) CNS Target Identification and Validation: Avoiding the Valley of Death or Naive Optimism?. Annual Review of Pharmacology and Toxicology 57:1, pages 171-187.
Crossref
Hee Ryung Wang, Young Sup Woo & Won-Myong Bahk. (2016) Ineffectiveness of nicotinic acetylcholine receptor antagonists for treatment-resistant depression. International Clinical Psychopharmacology 31:5, pages 241-248.
Crossref
Hyeong-Min Lee & Yuna Kim. (2016) Drug Repurposing Is a New Opportunity for Developing Drugs against Neuropsychiatric Disorders. Schizophrenia Research and Treatment 2016, pages 1-12.
Crossref
Han-Kun Zhang, Hendra Gunosewoyo, Fan Yan, Jie Tang & Li-Fang Yu. 2016. Nicotinic Acetylcholine Receptor Technologies. Nicotinic Acetylcholine Receptor Technologies 207 225 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.